Wednesday , December 8 2021

Disappointing studies – Curevac withdraws planned corona vaccine



[ad_1]

Published

The Curevac company has suffered a setback: it is withdrawing its candidate for the vaccine.

1 / 3

Together with the British pharmaceutical company GSK, Curevac is now focusing on developing candidates for the second generation of the vaccine.

Together with the British pharmaceutical company GSK, Curevac is now focusing on developing candidates for the second generation of the vaccine.

Sebastian Gollnov / dpa

According to the EMA, it can be assumed that the first developed vaccine, CVnCoV, will be able to get approval at the earliest in the second quarter of 2022.

According to the EMA, it can be assumed that the first developed vaccine, CVnCoV, will be able to get approval at the earliest in the second quarter of 2022.

20min / Simon Glauser

Like the company from Mainz Biontech, Curevac relies on a modern vaccine against mRNA.

Like the company from Mainz Biontech, Curevac also relies on a modern vaccine against mRNA.

20min / Simon Glauser

  • In the studies, the effectiveness of the planned vaccine from Curevac was disappointing.

  • Now the company is pulling the emergency brake.

  • Curevac is now working on another candidate.

The German pharmaceutical company Curevac is making a new attempt to introduce a corona vaccine. Together with the British pharmaceutical company GSK, Curevac is now concentrating on developing candidates for the second generation of the vaccine, as the company announced on Tuesday in Tübingen. The request for approval of the European Medicines Agency (EMA) for its first generation corona vaccine, which did not achieve the expected efficacy in the tests, is being withdrawn.

Approval at the earliest in the second quarter of 2022

According to the EMA, it can be assumed that the first developed vaccine, CVnCoV, will be able to get approval at the earliest in the second quarter of 2022. At this point, however, Curevac and GSK expect candidates in the second-generation vaccine program to have reached an advanced stage of clinical development. In addition, there is a greater need for differentiated vaccines for the upcoming endemic corona situation.

According to the company, the decision also ends the existing pre-agreement with the European Commission, in which CVnCoV was intended for acute pandemic needs. The two pharmaceutical manufacturers now want to accelerate the development and production of the second generation, which is also based on mRNA technology. They expect to be able to enter clinical development in the next few months.

Only 48 percent efficiency

The goal is to achieve regulatory approval for an improved vaccine against Covid-19 that will be ready for the market next year, Curevac and GSK explained. Compared with the first generation of mRNA vaccine, the second generation showed an immune response that was up to ten times higher in animal models.

Curevac’s efforts to market its coronavirus vaccine have fallen sharply over the summer. In late June, the Tübingen company announced that its corona vaccine was only 48 percent effective. Like the company from Mainz Biontech, Curevac also relies on a modern vaccine against mRNA. Tubingen’s medicine has long been considered extremely promising. Preparation Curevac does not play a role in the current vaccination campaign in Germany.

Do you or someone you know have problems with corona time?

(afp / lea)



[ad_2]
Source link